Immunoglobulin D

Athens Bioscience

Immunoglobulin D

9

Glycoproteomics, ELISA Standards, In Vitro Diagnostic, Hyperimmunoglobulinemia D Syndrome

Research Use Only

≥95% by SDS-PAGE

Serum IgD is a unique immunoglobulin with a low plasma concentration (~30 ug/mL) and a half-life of 2.8 days. Structurally, IgD features a long hinge region rich in O-linked glycans, conferring flexibility for antigen binding and interaction with immune cells. While predominantly expressed as a membrane-bound receptor on mature B cells alongside IgM, secreted IgD is produced by plasma cells in mucosal tissues and circulates at trace levels. IgD enhances humoral immunity by binding basophils and mast cells via galectin-9 and CD44, triggering antimicrobial peptide release (e.g., cathelicidin) and cytokines like IL-4, IL-5, and IL-13, which promote Th2-mediated responses5. Additionally, IgD induces IgD-receptor expression on T lymphocytes, amplifying B-T cell cooperation and antibody production. Dysregulated IgD is linked to hyperimmunoglobulinemia D syndrome (HIDS), an autoinflammatory disorder characterized by recurrent fever, elevated serum IgD (more then100 U/mL), and mutations in the mevalonate kinase gene. IgD also plays a role in IgD multiple myeloma, a rare plasma cell malignancy associated with lambda light chains, renal impairment, and poor prognosis. Clinically, serum IgD quantification aids in diagnosing HIDS and monitoring disease flares. Emerging therapeutic strategies target IgD-basophil interactions to modulate Th2 responses in allergies and autoimmune conditions. Despite its enigmatic role, IgD’s evolutionary conservation underscores its importance in bridging innate and adaptive immunity.

more then 1 year

Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

≤ -80° C

41116100